Eton Pharmaceuticals (NASDAQ:ETON) has announced the acquisition of Galzin, a rare disease product used in the treatment of Wilson disease.
The company reports that Galzin, an FDA-approved zinc acetate, is utilized as a maintenance therapy for patients with the ultra-rare metabolic disorder Wilson disease after initial treatment with a chelating agent. Approximately 5,000 patients in the U.S. are currently receiving treatment for Wilson disease. Eton plans to begin U.S. commercialization of the product in the first quarter of this year.
“This acquisition furthers our mission of supporting life-saving treatments for conditions impacting ultra-rare patient populations. Galzin is a critical medication for patients with Wilson disease, and we look forward to supporting these patients with our comprehensive Eton Cares patient support program,” said Sean Brynjelsen, CEO of Eton.”
